IDT Australia (ASX:IDT)

Executive Summary

IDT Australia (ASX:IDT) is a Melbourne-based contract development and manufacturing organisation (CDMO) with over 35 years of experience providing cGMP services from API production to finished dosage forms. Its 12,000 m² modular facility includes high-containment capabilities for oral solids, non-sterile liquids, sterile injectables, and radiopharmaceuticals, serving global pharma and biotech partners across pre-clinical to commercial stages. The company covers therapeutic areas including oncology, ophthalmology, neurology, metabolic disorders, and cardiovascular diseases, positioning it as a versatile partner in the growing CDMO market. Looking ahead, IDT Australia is well-positioned to benefit from the increasing outsourcing of pharmaceutical manufacturing, particularly in complex formulations such as radiopharmaceuticals and sterile injectables. Key catalysts include potential new long-term contracts with large pharmaceutical companies, expansion of its high-containment capacity to meet rising demand, and regulatory approvals (e.g., TGA or FDA) for additional manufacturing lines. With a solid operational history and a focus on niche capabilities, the company offers a steady growth profile, though execution risks remain tied to client wins and regulatory timelines.

Upcoming Catalysts (preview)

• Q3 2026Securing a major long-term radiopharmaceutical contract60% success
• Q4 2026Facility expansion to increase high-containment manufacturing capacity70% success
• Q2 2026Regulatory approval for new sterile injectable production line75% success